De novo extended-release Tacrolimus in Kidney Transplant Patients; Is it safe?
Background: This study aimed to investigate whether de novo extended-release tacrolimus (ERT) therapy is safe in kidney recipients. Methods: The study was single-center, retrospective, and included a total of 57 patients, including 30 patients in the ERT group (Group 1) and 27 patients in the immedi...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sakarya University
2023-09-01
|
| Series: | Sakarya Tıp Dergisi |
| Subjects: | |
| Online Access: | https://dergipark.org.tr/tr/download/article-file/3259408 |
| _version_ | 1827377818516848640 |
|---|---|
| author | Enes Sarıgedik Gözde Çakırsoy Çakar Zafer Ercan Kenan Evren Öztop Musa Pınar Hamad Dheir Necattin Fırat Mahmud İslam |
| author_facet | Enes Sarıgedik Gözde Çakırsoy Çakar Zafer Ercan Kenan Evren Öztop Musa Pınar Hamad Dheir Necattin Fırat Mahmud İslam |
| author_sort | Enes Sarıgedik |
| collection | DOAJ |
| description | Background: This study aimed to investigate whether de novo extended-release tacrolimus (ERT) therapy is safe in kidney recipients.
Methods: The study was single-center, retrospective, and included a total of 57 patients, including 30 patients in the ERT group (Group 1) and 27 patients in the immediate-release tacrolimus (IRT) group (Group 2). Demographic and laboratory characteristics of the patients were recorded. Complications such as acute drug toxicity, acute rejection, new-onset diabetes mellitus after transplantation, and development of hypertension, opportunistic infection, and hospitalization data were recorded.
Results: The mean age of the patients was 46.23±14.2 years in the ERT group and 47.04±14.6 years in the IRT group. There were 21 (70%) males in group 1, while 20 (74%) patients in group 2 had a male gender (P=0.73). The rate of improved serum creatinine values in the first week postoperatively was similar in both groups. While the mean tacrolimus levels on postoperative day 1 were significantly lower in the group- 1 (P lt;0.05), there was no significant difference between tacrolimus levels on postoperative days 2-7. There was no significant difference between the groups regarding opportunistic infections, diabetes mellitus, and the need for hospitalization in the first six months of follow-up.
Conclusion: Initiation of de novo extended-release tacrolimus therapy in kidney recipients is safe in the long term and preserves graft function. |
| first_indexed | 2024-03-08T12:45:48Z |
| format | Article |
| id | doaj.art-deaca066868d47c0998184d05a5e5815 |
| institution | Directory Open Access Journal |
| issn | 2146-409X |
| language | English |
| last_indexed | 2024-03-08T12:45:48Z |
| publishDate | 2023-09-01 |
| publisher | Sakarya University |
| record_format | Article |
| series | Sakarya Tıp Dergisi |
| spelling | doaj.art-deaca066868d47c0998184d05a5e58152024-01-21T07:40:07ZengSakarya UniversitySakarya Tıp Dergisi2146-409X2023-09-0113347848310.31832/smj.132632028De novo extended-release Tacrolimus in Kidney Transplant Patients; Is it safe?Enes Sarıgedik0Gözde Çakırsoy Çakar1Zafer Ercan2Kenan Evren Öztop3Musa Pınar4Hamad Dheir5Necattin Fırat6Mahmud İslam7SAKARYA ÜNİVERSİTESİ, TIP FAKÜLTESİ, TIP PR.SAKARYA ÜNİVERSİTESİ, TIP FAKÜLTESİ, TIP PR.SAKARYA ÜNİVERSİTESİ, TIP FAKÜLTESİ, TIP PR.SAKARYA ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜSAKARYA ÜNİVERSİTESİ, TIP FAKÜLTESİ, TIP PR.SAKARYA ÜNİVERSİTESİ, TIP FAKÜLTESİ, TIP PR.SAKARYA UNIVERSITY, SCHOOL OF MEDICINE, MEDICINE PR.SAKARYA UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINEBackground: This study aimed to investigate whether de novo extended-release tacrolimus (ERT) therapy is safe in kidney recipients. Methods: The study was single-center, retrospective, and included a total of 57 patients, including 30 patients in the ERT group (Group 1) and 27 patients in the immediate-release tacrolimus (IRT) group (Group 2). Demographic and laboratory characteristics of the patients were recorded. Complications such as acute drug toxicity, acute rejection, new-onset diabetes mellitus after transplantation, and development of hypertension, opportunistic infection, and hospitalization data were recorded. Results: The mean age of the patients was 46.23±14.2 years in the ERT group and 47.04±14.6 years in the IRT group. There were 21 (70%) males in group 1, while 20 (74%) patients in group 2 had a male gender (P=0.73). The rate of improved serum creatinine values in the first week postoperatively was similar in both groups. While the mean tacrolimus levels on postoperative day 1 were significantly lower in the group- 1 (P lt;0.05), there was no significant difference between tacrolimus levels on postoperative days 2-7. There was no significant difference between the groups regarding opportunistic infections, diabetes mellitus, and the need for hospitalization in the first six months of follow-up. Conclusion: Initiation of de novo extended-release tacrolimus therapy in kidney recipients is safe in the long term and preserves graft function.https://dergipark.org.tr/tr/download/article-file/3259408böbrek nakliuzatılmış salımlı takrolimushızlı salımlı takrolimusgreft fonksiyonu.kidney transplantationextended-release tacrolimusimmediate-release tacrolimus |
| spellingShingle | Enes Sarıgedik Gözde Çakırsoy Çakar Zafer Ercan Kenan Evren Öztop Musa Pınar Hamad Dheir Necattin Fırat Mahmud İslam De novo extended-release Tacrolimus in Kidney Transplant Patients; Is it safe? Sakarya Tıp Dergisi böbrek nakli uzatılmış salımlı takrolimus hızlı salımlı takrolimus greft fonksiyonu. kidney transplantation extended-release tacrolimus immediate-release tacrolimus |
| title | De novo extended-release Tacrolimus in Kidney Transplant Patients; Is it safe? |
| title_full | De novo extended-release Tacrolimus in Kidney Transplant Patients; Is it safe? |
| title_fullStr | De novo extended-release Tacrolimus in Kidney Transplant Patients; Is it safe? |
| title_full_unstemmed | De novo extended-release Tacrolimus in Kidney Transplant Patients; Is it safe? |
| title_short | De novo extended-release Tacrolimus in Kidney Transplant Patients; Is it safe? |
| title_sort | de novo extended release tacrolimus in kidney transplant patients is it safe |
| topic | böbrek nakli uzatılmış salımlı takrolimus hızlı salımlı takrolimus greft fonksiyonu. kidney transplantation extended-release tacrolimus immediate-release tacrolimus |
| url | https://dergipark.org.tr/tr/download/article-file/3259408 |
| work_keys_str_mv | AT enessarıgedik denovoextendedreleasetacrolimusinkidneytransplantpatientsisitsafe AT gozdecakırsoycakar denovoextendedreleasetacrolimusinkidneytransplantpatientsisitsafe AT zaferercan denovoextendedreleasetacrolimusinkidneytransplantpatientsisitsafe AT kenanevrenoztop denovoextendedreleasetacrolimusinkidneytransplantpatientsisitsafe AT musapınar denovoextendedreleasetacrolimusinkidneytransplantpatientsisitsafe AT hamaddheir denovoextendedreleasetacrolimusinkidneytransplantpatientsisitsafe AT necattinfırat denovoextendedreleasetacrolimusinkidneytransplantpatientsisitsafe AT mahmudislam denovoextendedreleasetacrolimusinkidneytransplantpatientsisitsafe |